Malignant pheochromocytoma is a tumour with a very low incidence that occurs sporadically or in the presence of multiple endocrine neoplasia. We present the case of a woman with a sporadic occurrence of pheochromocytoma diagnosed in the phase of multiple dissemination in the abdominal cavity and overexpressing adrenaline, noradrenaline, and dopamine. Local transarterial chemoembolization and systemic treatment with lanreotide resulted in a very good response, a decrease in the production of catecholamines for 12 months and a partial decrease for another 8 months, with stabilization of disease determined by imaging. Systemic treatment with tegafur resulted in disease stabilization lasting 50 months, after which the drug was discontinued because of adverse effects. Maintenance therapy with lanreotide continues, and no disease progression has been observed for 4 months. The treatment algorithm for such patients is multidisciplinary and must always take into account the current scope of the disease, intercurrence, and the general condition of the patient.

Medical Faculty Masaryk University Brno Czech Republic; ; Department of Radiology University Hospital Brno Brno Czech Republic

Medical Faculty Masaryk University Brno Czech Republic; ; Institute of Pathology University Hospital Brno Brno Czech Republic;

Medical Faculty Masaryk University Brno Czech Republic; ; Internal Hematological and Oncological Clinic University Hospital Brno Brno Czech Republic;

Zobrazit více v PubMed

Jiang S, Dahia PL. Minireview: the busy road to pheochromocytomas and paragangliomas has a new member, TMEM127. Endocrinology. 2011;152:2133–40. doi: 10.1210/en.2011-0052. PubMed DOI

Jimenez C, Rohren E, Habra MA, et al. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep. 2013;15:356–71. doi: 10.1007/s11912-013-0320-x. PubMed DOI

Musil Z, Vícha A, Zelinka T, et al. Hereditary pheochromocytoma and paraganglioma [Czech] Klin Onkol. 2012;25(suppl):S21–6. PubMed

Tanaka S, Ito T, Tomoda J, Higashi T, Yamada G, Tsuji T. Malignant pheochromocytoma with hepatic metastasis diagnosed 20 years after resection of the primary adrenal lesion. Intern Med. 1993;32:789–94. doi: 10.2169/internalmedicine.32.789. PubMed DOI

Hoffmann RT, Paprottka P, Jakobs TF, Trumm CG, Reiser MF. Arterial therapies of non-colorectal cancer metastases to the liver (from chemoembolization to radioembolization) Abdom Imaging. 2011;36:671–6. doi: 10.1007/s00261-011-9753-6. PubMed DOI

Huang H, Abraham J, Hung E, et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer. 2008;113:2020–8. doi: 10.1002/cncr.23812. PubMed DOI PMC

Gonias S, Goldsby R, Matthay KK, et al. Phase ii study of high-dose 131I-metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27:4162–8. doi: 10.1200/JCO.2008.21.3496. PubMed DOI PMC

Averbuch SD, Steakley CS, Young RC, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med. 1988;109:267–73. doi: 10.7326/0003-4819-109-4-267. PubMed DOI

Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mtor inhibitor everolimus (rad001) Horm Metab Res. 2009;41:697–702. doi: 10.1055/s-0029-1220687. PubMed DOI

Joshua AM, Ezzat S, Asa SL, et al. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab. 2009;94:5–9. doi: 10.1210/jc.2008-1836. PubMed DOI

Buscombe JR, Cwikla JB, Caplin ME, Hilson AJ. Long-term efficacy of low activity meta-131I–iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nucl Med Commun. 2005;26:969–76. doi: 10.1097/01.mnm.0000184941.06123.b9. PubMed DOI

Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer. 2006;13(suppl 1):125–35. doi: 10.1677/erc.1.01324. PubMed DOI

Bukowski RM, Vidt DG. Chemotherapy trials in malignant pheochromocytoma: report of two patients and review of the literature. J Surg Oncol. 1984;27:89–92. doi: 10.1002/jso.2930270207. PubMed DOI

Pasquali D, Rossi V, Conzo G, et al. Effects of somatostatin analog som230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells. J Mol Endocrinol. 2008;40:263–71. PubMed

Invitti C, De Martin I, Bolla GB, et al. Effect of octreotide on catecholamine plasma levels in patients with chromaffin cell tumors. Horm Res. 1993;40:156–60. doi: 10.1159/000183786. PubMed DOI

Lamarre-Cliche M, Gimenez-Roqueplo AP, Billaud E, Baudin E, Luton JP, Plouin PF. Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma. Clin Endocrinol (Oxf) 2002;57:629–34. doi: 10.1046/j.1365-2265.2002.01658.x. PubMed DOI

Nakane M, Takahashi S, Sekine I, et al. Successful treatment of malignant pheochromocytoma with combination chemotherapy containing anthracycline. Ann Oncol. 2003;14:1449–51. doi: 10.1093/annonc/mdg358. PubMed DOI

Lowery AJ, Walsh S, McDermott EW, Prichard RS. Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas. Oncologist. 2013;18:391–407. doi: 10.1634/theoncologist.2012-0410. PubMed DOI PMC

Hidaka S, Hiraoka A, Ochi H, et al. Malignant pheochromocytoma with liver metastasis treated by transcatheter arterial chemo-embolization (tace) Intern Med. 2010;49:645–51. doi: 10.2169/internalmedicine.49.3061. PubMed DOI